Industry news

Recently, the "2024 Tenth China's Most Influential Pharmaceutical Enterprises Top 100 List" co-sponsored by the China Board of Directors Network and the China Data Research Center was officially announced in Beijing. Yiling Pharmaceutical made it to the top 100 list with its outstanding innovation capabilities and international development strategies.

Since its first introduction in 2015, the "China's Most Influential Pharmaceutical Enterprises Top 100 List" has attracted widespread attention both inside and outside the industry due to its authority and professionalism. The selection process for this list starts from the perspective of building a "Healthy China" ecosystem, predicting and analyzing industrial trends, and exploring new paths for integration in various branches of the pharmaceutical industry in a multidimensional and three-dimensional manner. As an innovative pharmaceutical enterprise on this list, Yiling Pharmaceutical has developed rapidly in recent years and become a representative force in the pharmaceutical industry.

Rooted in Innovation Concept with Abundant R&D Achievements In promoting the continuous development of traditional Chinese medicine theory and practice, Yiling Pharmaceutical always adheres to equal emphasis on inheritance and innovation of traditional Chinese medicine. It has systematically constructed the theoretical system of collateral disease for the first time，and established an integrated operation mode of "theory - clinical - scientific research - industry - teaching". This innovative model not only promotes modernization of traditional Chinese medicine theory but also provides solid theoretical foundation for new drug research & development (R&D). Relying on collateral disease theory，Yiling Pharmaceutic R&Dd a series of new drugs with independent intellectual property rights such as Tongxinluo Capsules、Lianhua Qingwen Particle/Capsules、Jinlida Granule etc. These new drugs cover multiple clinical significant diseases fields including cardiovascular & cerebrovascular diseases、respiratory system diseases、tumor、diabetes mellitus etc forming highly competitive product matrix . At present .Yiling Pharmiceutic has R&Dd listed more than ten kinds o innovative chinese patent medicine varieties among them there are still many ne w drugs undergoing critical stages o R& D or clinical trials .Furthermore ,among them eleven varieties were selected into t he latest national medical insurance drug Catalogue(2024 edition),which further reflects t he market recognition degree influence o their products .The achievement o these results can not be separated from Yi lin gPharmacueti cal'S persistent pursuit fo technological innovation strict control over product quality .

Build International Bridge Towards Globalization Of TCM:In terms o internationalizatio n aspect equally remarkable achievement have been made by ylnling phar maceutic constructe theoretical system o collateral diseas e which ha been widely recognized at home also develop vigorously abroad currently promotion core concept based societies relat edto study have establishe d mult iple countri es regions include united states canada european countries etc where inter nation al forum high peak academic exchange seminar held frequently among them internationa l conference relat ed studies ha ve been hel d successivelly twenty session becoming well know brand academic meeting within traditiona lchinese medicina circle additionally active cooperation resear ch carried out betwee n mu ltipl einternationa medical science resea rch institutions jointly published mor ethan three hundred si papers those cooperatio n activities enhance internationa influence ylnlingpharma ce u ti cal create prerequisite conditio nsfor global spread applicatio ntraditional chinese medicin overall during ongoing process advancement toward globalizatio necore products liketong xingluo capsulelianhuaqing wenc ao /granule entereoverfiftycountriesregion showinggreatpotentialglobalmarkthoseproductsuccessfulexpansionabroadbringsubstantialeconomicbenefitslnylin gpharmasine whilesetgoodexampleforothertraditionalchinesemedicineenterprisesindustryintermsoglobalizatio nacoursi ngtounderstandtheselectionprocesssciencerigorousexpertcommitteemethodcaculateweightaggregatedrawlistspeciallynvit mediafieldexpertparticipate supervisionensureobjectivefairnessrationalitysuchmechanism enableidentifyoutstandingperformerwithindustryfurtherpromotedevelopmentinnovationglobalizatio naspectsphar maceutica lindustryoverall.